Literature DB >> 8790845

Total rectal resection, mesorectum excision, and coloendoanal anastomosis: a therapeutic option for the treatment of low rectal cancer.

E Leo1, F Belli, S Andreola, M T Baldini, G F Gallino, R Giovanazzi, L Mascheroni, R Patuzzo, M Vitellaro, C Lavarino, R Bufalino.   

Abstract

BACKGROUND: There is recent and sporadic evidence indicating that patients with very low rectal cancer may be treated via a sphincter-saving procedure, obviating the need for abdominoperineal resection and definitive colostomy. This study confirms these findings.
METHODS: From March 1990 to October 1994, 79 patients affected with primary low rectal cancers were submitted for total rectal resection, mesorectum excision, and coloendoanal anastomosis. All lesions were located within 8 cm of the anal verge (within 6 cm in 64 cases).
RESULTS: Eight patients relapsed at the pelvic level, and one patient only at the paraanastomotic site. Postoperative morbidity attributable to the procedure was low. A perfect continence was documented in 66% of cases after colostomy closure, and many patients (63%) had one or two bowel movements a day. Sixty-two patients of this series are alive, 49 without actual evidence of disease. Follow-up ranged from 2 to 56 months (median 23).
CONCLUSIONS: The clinical and pathological data derived from this study suggest that radical mesorectum excision more than a large clearance margin of resection remains the most important factor in reducing the incidence of local relapse after low rectal cancer surgery and that total rectal resection and coloendoanal anastomosis is a suitable and safe option to traditional, demolitive surgical techniques.

Entities:  

Mesh:

Year:  1996        PMID: 8790845     DOI: 10.1007/bf02305662

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  51 in total

1.  Excision of the rectum with colonic J pouch-anal anastomosis for adenocarcinoma of the low and mid rectum.

Authors:  A Berger; E Tiret; R Parc; P Frileux; L Hannoun; B Nordlinger; R Ratelle; R Simon
Journal:  World J Surg       Date:  1992 May-Jun       Impact factor: 3.352

2.  Trans-sphincteric surgery of the rectum. (with 2 colour plates)

Authors:  A Y Mason
Journal:  Prog Surg       Date:  1974

3.  The size of regional lymph nodes does not correlate with the presence or absence of metastasis in lymph nodes in rectal cancer.

Authors:  H Kotanagi; T Fukuoka; Y Shibata; T Yoshioka; O Aizawa; Y Saito; G E Tur; K Koyama
Journal:  J Surg Oncol       Date:  1993-12       Impact factor: 3.454

4.  Local recurrence following 'curative' surgery for large bowel cancer: II. The rectum and rectosigmoid.

Authors:  R K Phillips; R Hittinger; L Blesovsky; J S Fry; L P Fielding
Journal:  Br J Surg       Date:  1984-01       Impact factor: 6.939

5.  Association between extent of colonic mucosal sialomucin change and subsequent local recurrence after curative excision of primary colorectal cancer.

Authors:  P M Dawson; N A Habib; S Fane; H C Rees; C B Wood; T G Allen-Mersh
Journal:  Br J Surg       Date:  1990-11       Impact factor: 6.939

6.  Mesorectal excision for rectal cancer.

Authors:  J K MacFarlane; R D Ryall; R J Heald
Journal:  Lancet       Date:  1993-02-20       Impact factor: 79.321

7.  The value of a study of the mucosubstances in rectal biopsies from patients with carcinoma of the rectum and lower sigmoid in the diagnosis of premalignant mucosa.

Authors:  M I Filipe
Journal:  J Clin Pathol       Date:  1972-02       Impact factor: 3.411

8.  Pullthrough operation with delayed anastomosis for rectal cancer.

Authors:  W O Kirwan; R B Turnbull; V W Fazio; F L Weakley
Journal:  Br J Surg       Date:  1978-10       Impact factor: 6.939

9.  Total rectal resection and colo-anal anastomosis with colonic reservoir for low rectal cancer.

Authors:  E Leo; F Belli; M T Baldini; M Vitellaro; L Mascheroni; S Andreola; M Bellomi; G Rebuffoni; F Lombardi; R Audisio
Journal:  Int J Colorectal Dis       Date:  1994-05       Impact factor: 2.571

10.  Local recurrence after potentially curative resection for rectal cancer in a series of 1008 patients.

Authors:  F T McDermott; E S Hughes; E Pihl; W R Johnson; A B Price
Journal:  Br J Surg       Date:  1985-01       Impact factor: 6.939

View more
  2 in total

1.  A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial.

Authors:  Julio Garcia-Aguilar; Qian Shi; Charles R Thomas; Emily Chan; Peter Cataldo; Jorge Marcet; David Medich; Alessio Pigazzi; Samuel Oommen; Mitchell C Posner
Journal:  Ann Surg Oncol       Date:  2011-07-14       Impact factor: 5.344

2.  Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.

Authors:  Julio Garcia-Aguilar; Zhenbin Chen; David D Smith; Wenyan Li; Robert D Madoff; Peter Cataldo; Jorge Marcet; Carlos Pastor
Journal:  Ann Surg       Date:  2011-09       Impact factor: 12.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.